AstraZeneca PLC
AZN
$189.90
-$2.60-1.35%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.33B | 2.53B | 2.45B | 2.92B | 1.50B |
| Total Depreciation and Amortization | 1.17B | 1.55B | 1.39B | 1.28B | 630.00M |
| Total Amortization of Deferred Charges | 236.00M | -- | -- | -- | 200.00M |
| Total Other Non-Cash Items | -189.00M | 217.00M | -108.00M | -61.00M | 927.00M |
| Change in Net Operating Assets | -1.20B | 835.00M | -345.00M | -426.00M | -350.00M |
| Cash from Operations | 2.34B | 5.13B | 3.39B | 3.71B | 2.91B |
| Capital Expenditure | -1.04B | -686.00M | -659.00M | -429.00M | -708.00M |
| Sale of Property, Plant, and Equipment | 3.00M | 0.00 | 9.00M | 1.00M | 2.00M |
| Cash Acquisitions | -273.00M | -328.00M | -267.00M | -362.00M | -274.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -140.00M | -987.00M | -1.19B | -463.00M | -201.00M |
| Cash from Investing | -1.45B | -2.00B | -2.11B | -1.25B | -1.18B |
| Total Debt Issued | -1.01B | -352.00M | 644.00M | 1.10B | -572.00M |
| Total Debt Repaid | -2.11B | -93.00M | -115.00M | -85.00M | -119.00M |
| Issuance of Common Stock | 23.00M | 5.00M | 4.00M | 8.00M | 23.00M |
| Repurchase of Common Stock | -13.00M | -19.00M | -3.00M | -486.00M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -1.61B | -10.00M | -3.35B | -3.00M |
| Other Financing Activities | -294.00M | -3.00M | -2.00M | 104.00M | -27.00M |
| Cash from Financing | -3.28B | -2.07B | 518.00M | -2.71B | -671.00M |
| Foreign Exchange rate Adjustments | 4.00M | -12.00M | 29.00M | 25.00M | -61.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.38B | 1.05B | 1.83B | -222.00M | 994.00M |